The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
Abstract
A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers. Because of the small number of patients in that trial, a larger phase 3 trial was performed to confirm these results. Two hundred forty patients were randomized to receive either BCNU or placebo wafers at the time of primary surgical resection; both groups were treated with external beam radiation postoperatively. The two groups were similar for age, sex, Karnofsky performance status (KPS), and tumor histology. Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P -value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% ( P = 0.03). Time to decline in KPS and in 10/11 neuroperformance measures was statistically significantly prolonged in the BCNU wafer-treated group ( P </= 0.05). Adverse events were comparable for the 2 groups, except for CSF leak (5% in the BCNU wafer-treated group vs. 0.8% in the placebo-treated group) and intracranial hypertension (9.1% in the BCNU wafer-treated group vs. 1.7% in the placebo group). This study confirms that local chemotherapy with BCNU wafers is well tolerated and offers a survival benefit to patients with newly diagnosed malignant glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., et al. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012043032303 · Cited by 1,611
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
Self-citationPathology and genetics of tumours of the nervous system.
Kleihues, P., & Cavennee, W. (2000) · International Agency for Research on Cancer eBooks · Cited by 1,432
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Assumptions in the radiotherapy of glioblastoma
Hochberg, F. H., & Pruitt, A. (1980) · Neurology · doi:10.1212/wnl.30.9.907 · Cited by 992
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Self-citation
Cited by
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Glioblastoma and Other Malignant Gliomas: A Clinical Review
Omuro, A. (2013) · JAMA · doi:10.1001/jama.2013.280319 · Cited by 2,301
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00447-z · Cited by 2,048
Self-citationPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Primary brain tumours in adults
Lapointe, S., Perry, A., & Butowski, N. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30990-5 · Cited by 1,366
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Acharya, S., & Sahoo, S. K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.10.008 · Cited by 1,112
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationPolylactic acid (PLA) controlled delivery carriers for biomedical applications
Tyler, B., Gullotti, D., Mangraviti, A., Utsuki, T., & Brem, H. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.018 · Cited by 1,050
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Wolinsky, J. B., Colson, Y. L., & Grinstaff, M. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.031 · Cited by 845
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Alexander, B. M., & Cloughesy, T. F. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0119 · Cited by 788
Maier-Hauff, K., Rothe, R., Scholz, R., Gneveckow, U., Wust, P., Thiesen, B., Feussner, A., von Deimling, A., Waldoefner, N., Felix, R., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9195-0 · Cited by 775
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Weller, M., van den Bent, M., Hopkins, K., Tonn, J. C., Stupp, R., Falini, A., Cohen-Jonathan-Moyal, E., Frappaz, D., Henriksson, R., Balana, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70011-7 · Cited by 750
Self-citationFDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., Koh, C., Zhang, J., Li, Y.-M., Maciaczyk, J., et al. (2010) · Stem Cells · doi:10.1002/stem.254 · Cited by 651
Current and future strategies for treatment of glioma
Bush, N. A. O., Chang, S. M., & Berger, M. S. (2017) · Neurosurgical Review · doi:10.1007/s10143-016-0709-8 · Cited by 577
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Treat, L. H., McDannold, N., Vykhodtseva, N., Zhang, Y., Tam, K., & Hynynen, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22732 · Cited by 545
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
Todo, T., Ito, H., Ino, Y., Ohtsu, H., Ota, Y., Shibahara, J., & Tanaka, M. (2022) · Nature Medicine · doi:10.1038/s41591-022-01897-x · Cited by 526
Paclitaxel: a review of adverse toxicities and novel delivery strategies
Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M., & Brem, H. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.5.609 · Cited by 510
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Koshy, M., Villano, J. L., Dolecek, T. A., Howard, A., Mahmood, U., Chmura, S. J., Weichselbaum, R. R., & McCarthy, B. J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0738-7 · Cited by 481
Current concepts and management of glioblastoma
Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R. (2011) · Annals of Neurology · doi:10.1002/ana.22425 · Cited by 461
Grossman, S. A., Ye, X., Piantadosi, S., Desideri, S., Nabors, L. B., Rosenfeld, M., Fisher, J., & for the NABTT CNS Consortium (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3106 · Cited by 448
Active targeting of brain tumors using nanocarriers
Béduneau, A., Saulnier, P., & Benoit, J.-P. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.06.011 · Cited by 424
Westphal, M., Ram, Z., Riddle, V., Hilt, D., Bortey, E., & On behalf of the Executive Committee of the Gliadel® Study Group (2006) · Acta Neurochirurgica · doi:10.1007/s00701-005-0707-z · Cited by 420
Self-citationLiu, H.-L., Hua, M.-Y., Chen, P.-Y., Chu, P.-C., Pan, C.-H., Yang, H.-W., Huang, C.-Y., Wang, J.-J., Yen, T.-C., & Wei, K.-C. (2010) · Radiology · doi:10.1148/radiol.10090699 · Cited by 393
Stewart, S. A., Domínguez-Robles, J., Donnelly, R. F., & Larrañeta, E. (2018) · Polymers · doi:10.3390/polym10121379 · Cited by 390
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
“6 months for patients in the placebo group [209].”
Putting Electrospun Nanofibers to Work for Biomedical Research
Xie, J., Li, X., & Xia, Y. (2008) · Macromolecular Rapid Communications · doi:10.1002/marc.200800381 · Cited by 381
Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
Chang, S. M. (2005) · JAMA · doi:10.1001/jama.293.5.557 · Cited by 362
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles
van Landeghem, F. K. H., Maier-Hauff, K., Jordan, A., Hoffmann, K.-T., Gneveckow, U., Scholz, R., Thiesen, B., Brück, W., & von Deimling, A. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.044 · Cited by 355
Current approaches to enhance CNS delivery of drugs across the brain barriers
Lu, C.-T., Zhao, Y.-Z., Wong, H. L., Cai, J., Peng, L., & Tian, X.-Q. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s61288 · Cited by 350
5-ALA and FDA Approval for Glioma Surgery
Hadjipanayis, C. G., & Stummer, W. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03098-y · Cited by 338
Advancing the field of drug delivery
Moses, M. A., Brem, H., & Langer, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00276-9 · Cited by 343
Buckner, J. C., Brown, P. D., O'Neill, B. P., Meyer, F. B., Wetmore, C. J., & Uhm, J. H. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.10.1271 · Cited by 341
Electrospun Micro- and Nanofibers for Sustained Delivery of Paclitaxel to Treat C6 Glioma in Vitro
Xie, J., & Wang, C.-H. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9036-z · Cited by 339
Petrecca, K., Guiot, M.-C., Panet-Raymond, V., & Souhami, L. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0983-4 · Cited by 334
Advances in local therapy for glioblastoma — taking the fight to the tumour
van Solinge, T. S., Nieland, L., Chiocca, E. A., & Broekman, M. L. D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00621-0 · Cited by 334
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
Self-citationCombs, S. E., Thilmann, C., Edler, L., Debus, J., & Schulz-Ertner, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4157 · Cited by 325
Tumor microtubes convey resistance to surgical lesions and chemotherapy in gliomas
Weil, S., Osswald, M., Solecki, G., Grosch, J., Jung, E., Lemke, D., Ratliff, M., Hänggi, D., Wick, W., & Winkler, F. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox070 · Cited by 317
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Fisher, J. P., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030324 · Cited by 316
Anticancer Polymeric Nanomedicines
Tong, R., & Cheng, J. (2007) · Polymer Reviews · doi:10.1080/15583720701455079 · Cited by 310
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 307
Mechanisms regulating glioma invasion
Paw, I., Carpenter, R. C., Watabe, K., Debinski, W., & Lo, H.-W. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.03.015 · Cited by 306
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
McGirt, M. J., Than, K. D., Weingart, J. D., Chaichana, K. L., Attenello, F. J., Olivi, A., Laterra, J., Kleinberg, L. R., Grossman, S. A., Brem, H., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.5.17557 · Cited by 299
Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Agarwal, S., Sane, R., Oberoi, R., Ohlfest, J. R., & Elmquist, W. F. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001888 · Cited by 292
Ting, C.-Y., Fan, C.-H., Liu, H.-L., Huang, C.-Y., Hsieh, H.-Y., Yen, T.-C., Wei, K.-C., & Yeh, C.-K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.096 · Cited by 282
Liu, H.-L., Fan, C.-H., Ting, C.-Y., & Yeh, C.-K. (2014) · Theranostics · doi:10.7150/thno.8074 · Cited by 276
Sarin, H., Kanevsky, A. S., Wu, H., Brimacombe, K. R., Fung, S. H., Sousa, A. A., Auh, S., Wilson, C. M., Sharma, K., Aronova, M. A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-80 · Cited by 274
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 269
Understanding high grade glioma: Molecular mechanism, therapy and comprehensive management
Wang, Y., & Jiang, T. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.12.024 · Cited by 260
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161
Racial, ethnic and socioeconomic disparities in the treatment of brain tumors
Curry, W. T., & Barker, F. G. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9840-5 · Cited by 152
Biomaterial‐Based Implantable Devices for Cancer Therapy
Chew, S. A., & Danti, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600766 · Cited by 121
Chaichana, K. L., Pinheiro, L., & Brem, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.114 · Cited by 91
Targeted Therapies for Malignant Glioma: Progress and Potential
Mercer, R. W., Tyler, M. A., Ulasov, I. V., & Lesniak, M. S. (2009) · BioDrugs · doi:10.2165/00063030-200923010-00003 · Cited by 39
Applications and Efficacy of Iron Oxide Nanoparticles in the Treatment of Brain Tumors
Varalli, L., Berlet, R., Abenojar, E., McDaid, J., Gascoigne, D. A., Bailes, J., & Aksenov, D. P. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040499 · Cited by 23
Metadata
- Authors
- Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-04-01
- Volume
- 5
- Issue
- 2
- Pages
- 79-88
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2100567246
- Cited by
- 1,330
- References
- 23
- FWCI
- 24.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.